secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0000950170-24-079059
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Janux shareholders elect three Class III directors and ratify EY as auditor
---------------------------------------------------------------------------

- Class III directors elected: Vickie Capps, Jay Lichter, and Jake Simson, each with >41 million votes for.
- Ernst & Young ratified as independent auditor for FY2024 with 49,801,743 votes for, 1,682 against.
- 51,850,667 shares outstanding as of record date April 29, 2024; broker non-votes reported for director election.
- All proposals passed; no other business items were voted on at the 2024 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024079059/0000950170-24-079059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024079059/janx-20240626.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-079059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer